Orexigen Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 3,428 3,428 4,399 1,231
Cost of Revenue - - - -
Gross Profit 3,428 3,428 4,399 1,231
Operating Expenses
Research and Development 56,748 73,680 12,780 28,131
Sales, General and Admin. 23,878 19,987 19,502 24,495
Non-Recurring Items - - - -
Other - - - -
Operating Income (77,198) (90,239) (27,883) (51,395)
Income From Continuing Operations
Add'l Income/Expense Items 65 147 46 124
Earnings Before Interest and Tax (77,133) (90,092) (27,837) (51,271)
Interest Expense 538 2 221 644
Earnings Before Tax (77,671) (90,094) (28,058) (51,915)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (77,671) (90,094) (28,058) (51,915)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (77,671) (90,094) (28,058) (51,915)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (77,671) (90,094) (28,058) (51,915)